Compare Oruka Therapeutics Inc. Common Stock (ORKA) vs PubMatic Inc (PUBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oruka Therapeutics Inc. Common Stock vs PubMatic Inc — how do they compare? Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.08B), while PubMatic Inc trades at $17.61 (market cap $802.59M). The key difference: Oruka Therapeutics Inc. Common Stock is far larger — about 6.3× PubMatic Inc's market cap, and PubMatic Inc is trading nearer its 52-week high, Oruka Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Oruka Therapeutics Inc. Common Stock for 0 Days and PubMatic Inc for 40 Days on average.
| ORKA | PUBM | |
|---|---|---|
Market Cap | $5.08B | $802.59M |
Volume | 685,276 | 589,504 |
Sector | Health | Technology |
52-Week High | $113.08 | $19.18 |
52-Week Low | $26.19 | $6.28 |
Typical Hold Time | 0 Days | 40 Days |
Enterprise Value | $4.21B | $705.72M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
PUBM trades at $18.89, up 2.0% today, with a bullish technical setup and strong analyst consensus. Recent earnings beats and positive cash flow trends contrast with negative net income margins. The stock benefits from AI-driven ad tech growth and new leadership appointments, though it faces profitability challenges amid competitive pressures.
Outlook: Upside exists if profitability improves, supported by AI adoption and double-digit revenue growth in key segments. Risks include sustained losses, CFO transition, and ad market volatility. The consensus price target of $19.89 suggests modest near-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →
